Single-cell RNA sequencing (scRNA-seq) is a powerful tool for evaluating cell-type specific transcription but can be challenging to apply to rare cell populations. Efficient collection of low abundance cell types can be achieved by pooling biological samples, but this precludes resolution of sample origin together with phenotypic data. This limitation is particularly problematic in experiments in which biological or technical variation is expected to be high (e.g., disease models which vary in phenotypic severity, high throughput genetic perturbation screens, or human patient samples). One solution is sample multiplexing where each sample is tagged with a unique sequence barcode that is resolved bioinformatically. We have established a scRNA-seq sample multiplexing pipeline for mouse retinal ganglion cells (RGCs) using cholesterol-modified-oligos (CMOs). RGCs are a scarce and highly heterogenous cell type (~47 types) that represent less than 1% of all retinal cells. We found that CMOs labeled RGCs efficiently and did not have a significant impact on cell viability, gene expression, or cluster type representation. Through these assignments, we evaluated differential gene expression and identified transcriptional variance between RGCs of individual retinas both as a whole and within specific RGC types. Overall RGC type distributions and transcriptomic correlations between retinas were remarkably similar. Additionally, sample multiplexing enabled the identification of multiplets and resolution of key biological features such as sex-specific gene expression differences. In conclusion, we found that the addition of CMOs is not detrimental to scRNA-seq analysis and enabled the evaluation of differential gene expression among individual biological samples for a rare cell population. As single-cell transcriptomics are becoming a more widely used approach to research development and disease, sample multiplexing represents a useful method to enhance the precision of scRNA-seq analysis.